Breadth and function of antibody response to acute SARS-CoV-2 infection in humans

Journal article

The SARS-CoV-2 pandemic continues despite the presence of effective vaccines, and novel vaccine approaches may help to reduce viral spread and associated COVID-19 disease. Current vaccine administration modalities are based on systemic needle-administered immunisation which may be suboptimal for mucosal pathogens. Here we demonstrate in a mouse model that small-volume intranasal administration of purified spike (S) protein in the adjuvant polyethylenemine (PEI) elicits robust antibody responses with modest systemic neutralisation activity. Further, we test a heterologous intranasal immunisation regimen, priming with S and boosting with RBD-Fc. Our data identify small volume PEI adjuvantation as a novel platform with potential for protective mucosal vaccine development

Authors: Huang, K-YA; Tan, TK; Chen, T-H; Huang, C-G; Harvey, R

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Public Library of Science
• Journal: PLoS Pathogens
• Volume: 17
• Issue: 2
• Pages: e1009352-e1009352
• Publication date: 2021-02-26
• DOI: 10.1371/journal.ppat.1009352
• EISSN: 1553-7374
• ISSN: 1553-7366
• Language: English
• Keywords: Monoclonal antibody; Serology; Immunology; Virology; Biology; Titer; Virus; Antibody